日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks

罗氟司特泡沫剂0.3%治疗脂溢性皮炎患者的长期安全性和有效性：一项长达52周的II期开放标签试验

期刊:American Journal of Clinical Dermatology
影响因子:8.8
doi:10.1007/s40257-025-00984-2
Alexis, Andrew F; Bukhalo, Michael; Cook-Bolden, Fran E; Del Rosso, James Q; Draelos, Zoe D; DuBois, Janet C; Ferris, Laura K; Forman, Seth B; Kempers, Steven E; Kircik, Leon H; Lain, Edward; Moore, Angela Y; Pariser, David M; Raoof, Joseph; Zirwas, Matthew J; Seal, Melissa S; Kato, Saori; Chu, David H; Krupa, David; Snyder, Scott; Burnett, Patrick; Berk, David R
发表日期：2026
文献求助 收藏

Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

特拉洛奇尤单抗治疗中重度特应性皮炎患者长达6年的长期安全性和有效性：开放标签扩展试验ECZTEND的最终结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-026-01656-7
Blauvelt, Andrew; Hong, H Chih-Ho; Katoh, Norito; Langley, Richard G; Laquer, Vivian; Lesiak, Aleksandra; Peris, Ketty; Seneschal, Julien; Silvestre, Juan-Francisco; Warren, Richard B; Wollenberg, Andreas; Zirwas, Matthew; Bennike, Niels Højsager; Safavimanesh, Farzaneh; Tindberg, Ann-Marie; Reich, Kristian
发表日期：2026
文献求助 收藏

Lebrikizumab Improves Clinical Manifestations, Symptoms, and Quality of Life in Patients with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab: Results from the ADapt Study

利布利珠单抗可改善既往接受过度普利尤单抗治疗的中重度特应性皮炎患者的临床表现、症状和生活质量：ADapt 研究结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01644-3
Silverberg, Jonathan I; Ackerman, Lindsay; Bagel, Jerry; Stein Gold, Linda; Blauvelt, Andrew; Rosmarin, David; Chovatiya, Raj; Zirwas, Matthew; Yosipovitch, Gil; Waibel, Jill; Murase, Jenny E; Lockshin, Ben; Weisman, Jamie; Atwater, Amber Reck; Proper, Jennifer; Silk, Maria; Pierce, Evangeline; Piruzeli, Maria Lucia Buziqui; Montmayeur, Sonia; Schuster, Christopher; Zhong, Jinglin; Rueda, Maria Jose; Pillai, Sreekumar; Simpson, Eric
发表日期：2026
文献求助 收藏

Healthcare Resource Utilization and Economic Burden Across Clinical Phenotypes of Moderate-to-Severe Atopic Dermatitis in United States Dermatology Facilities

美国皮肤科机构中重度特应性皮炎不同临床表型的医疗资源利用和经济负担

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01590-0
Zirwas, Matthew; Lio, Peter; Rasouliyan, Lawrence; Althoff, Amanda G; Black, Danae A; Sabatelli, Lorenzo; Yosipovitch, Gil
发表日期：2026
文献求助 收藏

The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA)

一项为期 16 周的开放标签单臂 3 期研究 (INJECZTRA) 表明，Tralokinumab 预填充注射笔可改善中重度特应性皮炎成人和青少年患者的特应性皮炎体征和症状，且耐受性良好。

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-025-01490-3
Soung, Jennifer; Laquer, Vivian; Zirwas, Matthew; van Iperen, Peter; Stinson, John C; Albertsen, Katrine Lykke; Stein Gold, Linda
发表日期：2025
文献求助 收藏

Patient and Healthcare Provider Perspectives on Disease Burden of Seborrheic Dermatitis in the United States: Results from a National Survey

美国患者和医疗保健提供者对脂溢性皮炎疾病负担的看法：一项全国性调查的结果

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-024-01288-9
Polaskey, Meredith T; Aldredge, Lakshi; Heath, Candrice; Acevedo, Moises; Chu, David H; Hanna, Diane; Seal, Melissa S; Zirwas, Matthew; Chovatiya, Raj
发表日期：2024
文献求助 收藏

Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis

两项针对轻度至重度斑块状银屑病成人患者的3期临床试验表明，每日一次使用1%他匹那罗夫乳膏可快速改善瘙痒症状。

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-01068-x
Kircik, Leon; Zirwas, Matthew; Kwatra, Shawn G; Lewitt, G Michael; Glover, Holly; Chao, Tomas; Brown, Philip M; Rubenstein, David S; Tallman, Anna M
银屑病
发表日期：2024
文献求助 收藏

Patient and Healthcare Provider Perspectives on the Pathway to Diagnosis of Seborrheic Dermatitis in the United States

美国患者和医疗保健提供者对脂溢性皮炎诊断途径的看法

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-02986-8
Chovatiya, Raj; Polaskey, Meredith T; Aldredge, Lakshi; Heath, Candrice; Acevedo, Moises; Chu, David H; Hanna, Diane; Seal, Melissa S; Zirwas, Matthew
发表日期：2024
文献求助 收藏

Evaluation of the Safety and Tolerability of Lumify Eye Illuminations Cosmetic Products

Lumify Eye Illuminations 化妆品的安全性和耐受性评估

期刊:
影响因子:
doi:10.2147/OPTH.S481806
Wesley, Gina; Toyos, Melissa Morrison; DiVito, Melinda M; Zirwas, Matthew
发表日期：2024
文献求助 收藏

Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial

罗氟司特泡沫剂（0.3%）治疗脂溢性皮炎患者的疗效：一项双盲、赋形剂对照的 2a 期随机临床试验

期刊:Jama Dermatology
影响因子:11
doi:10.1001/jamadermatol.2023.0846
Zirwas, Matthew J; Draelos, Zoe D; DuBois, Janet; Kircik, Leon H; Moore, Angela Y; Stein Gold, Linda; Alonso-Llamazares, Javier; Bukhalo, Michael; Bruce, Suzanne; Eads, Kimmie; Green, Lawrence J; Guenthner, Scott T; Ferris, Laura K; Forman, Seth B; Kempers, Steven E; Lain, Edward; Lynde, Charles W; Pariser, David M; Toth, Darryl P; Yamauchi, Paul S; Higham, Robert C; Krupa, David; Burnett, Patrick; Berk, David R
发表日期：2023
文献求助 收藏